Hematologic Oncology | Specialty

Novel Approaches Emerge in AL Amyloidosis

April 27th 2018

Michael Rosenzweig, MD, discusses emerging treatment options for patients with immunoglobulin light chain amyloidosis such as daratumumab and NEOD001.

Dr. Rosenzweig Discusses Emerging Agents in Amyloidosis

April 27th 2018

Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.

Dr. Ai on Single-Agent and Combination Therapy in Patients With MDS

April 27th 2018

Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Future Direction for Polycythemia Vera

April 26th 2018

PV: Treatment With Ruxolitinib

April 26th 2018

Rationale for JAK Inhibition in PV

April 26th 2018

PV: Clinical Use of Hydroxyurea

April 26th 2018

Clinical Control of Polycythemia Vera

April 26th 2018

Initial Approach to PV Treatment

April 26th 2018

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

April 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

Gemtuzumab Ozogamicin Approved in Europe for CD33+ AML

April 25th 2018

The European Commission has approved the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg) for use in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and older with newly diagnosed, CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia.

Hamlin Discusses Practice-Changing Data in Lymphoma

April 25th 2018

Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.

Following FDA Approvals, CML Pipeline Has Challenges

April 25th 2018

Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.

FDA Approval Sought for Gilteritinib in FLT3+ AML

April 24th 2018

A new drug application has been filed with the FDA for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

April 24th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

FDA Halts Enrollment on Tazemetostat Trials

April 24th 2018

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

Expert Highlights Advances Across Lymphoma Subtypes

April 23rd 2018

Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.

Expert Highlights Evolving Role of BMT in Hematologic Malignancies

April 20th 2018

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

FDA Approves Fostamatinib for Chronic ITP

April 18th 2018

The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.